An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?

Abstract

Cite this article as: Bosschieter J, van Moorselaar RJ, Nieuwenhuijzen JA. An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit? Transl Androl

Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer

“…Discussion regarding conflicting data taken from the largest meta-analysis and the largest RCT conducted so far were published [230][231][232] , recommending SIC for all low-risk patients (LE 1; strong recommendation) and intermediate-risk patients regardless of whether further adjuvant intravesical chemotherapy is given (LE 2; weak recommendation). Patients who fall in the highrisk category but meet the criteria of EORTC score for recurrence < 5 may be considered for SIC (available at http://www.eortc.be/tools/bladdercalculator/) (LE 3; weak recommendation).…”